New and emerging agents in the management of lipodystrophy in HIV-infected patients

Eric BonnetService des Maladies Infectieuses, H&ocirc;pital Purpan, Toulouse, FranceAbstract: Lipodystrophy remains a major long-term complication in human immunodeficiency virus-infected patients under antiretroviral (ARV) therapy. Patients may present with lipoatrophy or lipohypertrophy or...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Eric Bonnet
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2010
Materias:	Immunologic diseases. Allergy RC581-607
Acceso en línea:	https://doaj.org/article/f03608686cca45cab58549814dd65794
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f03608686cca45cab58549814dd65794
record_format	dspace
spelling	oai:doaj.org-article:f03608686cca45cab58549814dd657942021-12-02T06:47:30ZNew and emerging agents in the management of lipodystrophy in HIV-infected patients1179-1373https://doaj.org/article/f03608686cca45cab58549814dd657942010-09-01T00:00:00Zhttp://www.dovepress.com/new-and-emerging-agents-in-the-management-of-lipodystrophy-in-hiv-infe-a5292https://doaj.org/toc/1179-1373Eric BonnetService des Maladies Infectieuses, H&ocirc;pital Purpan, Toulouse, FranceAbstract: Lipodystrophy remains a major long-term complication in human immunodeficiency virus-infected patients under antiretroviral (ARV) therapy. Patients may present with lipoatrophy or lipohypertrophy or both. The choice of treatments to improve fat redistribution depends on the form of lipodystrophy and its duration. Measures known to improve lipoatrophy are switches in ARV therapy (stavudine or zidovudine to abacavir or tenofovir) and filling interventions. Pioglitazone may be added to these measures, although any benefits appear small. Uridine and leptin were found to be disappointing so far. Regarding lipohypertrophy, diet and exercise, recombinant human growth hormone, and metformin may reduce visceral fat, but may worsen subcutaneous lipoatrophy. Surgical therapy may be required. Attractive pharmacologic treatments include growth hormone-releasing factor and leptin. Adiponectin and adiponectin receptors are promising therapeutic targets to explore.Keywords: lipoatrophy, lipohypertrophy, lipodystrophy, treatment, HIV, AIDS Eric BonnetDove Medical PressarticleImmunologic diseases. AllergyRC581-607ENHIV/AIDS: Research and Palliative Care, Vol 2010, Iss default, Pp 167-178 (2010)
institution	DOAJ
collection	DOAJ
language	EN
topic	Immunologic diseases. Allergy RC581-607
spellingShingle	Immunologic diseases. Allergy RC581-607 Eric Bonnet New and emerging agents in the management of lipodystrophy in HIV-infected patients
description	Eric BonnetService des Maladies Infectieuses, H&ocirc;pital Purpan, Toulouse, FranceAbstract: Lipodystrophy remains a major long-term complication in human immunodeficiency virus-infected patients under antiretroviral (ARV) therapy. Patients may present with lipoatrophy or lipohypertrophy or both. The choice of treatments to improve fat redistribution depends on the form of lipodystrophy and its duration. Measures known to improve lipoatrophy are switches in ARV therapy (stavudine or zidovudine to abacavir or tenofovir) and filling interventions. Pioglitazone may be added to these measures, although any benefits appear small. Uridine and leptin were found to be disappointing so far. Regarding lipohypertrophy, diet and exercise, recombinant human growth hormone, and metformin may reduce visceral fat, but may worsen subcutaneous lipoatrophy. Surgical therapy may be required. Attractive pharmacologic treatments include growth hormone-releasing factor and leptin. Adiponectin and adiponectin receptors are promising therapeutic targets to explore.Keywords: lipoatrophy, lipohypertrophy, lipodystrophy, treatment, HIV, AIDS
format	article
author	Eric Bonnet
author_facet	Eric Bonnet
author_sort	Eric Bonnet
title	New and emerging agents in the management of lipodystrophy in HIV-infected patients
title_short	New and emerging agents in the management of lipodystrophy in HIV-infected patients
title_full	New and emerging agents in the management of lipodystrophy in HIV-infected patients
title_fullStr	New and emerging agents in the management of lipodystrophy in HIV-infected patients
title_full_unstemmed	New and emerging agents in the management of lipodystrophy in HIV-infected patients
title_sort	new and emerging agents in the management of lipodystrophy in hiv-infected patients
publisher	Dove Medical Press
publishDate	2010
url	https://doaj.org/article/f03608686cca45cab58549814dd65794
work_keys_str_mv	AT ericbonnet newandemergingagentsinthemanagementoflipodystrophyinhivinfectedpatients
_version_	1718399788213338112

New and emerging agents in the management of lipodystrophy in HIV-infected patients

Ejemplares similares